Sign In
Buy ALT
$2.84
-0.140 (-4.70%)
At Close: Jul 31, 2026
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
01:02pm, Thursday, 12'th Mar 2026
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Altimmune Q4 Earnings Call Highlights
04:49am, Saturday, 07'th Mar 2026
Altimmune (NASDAQ: ALT) executives used the company's year-end 2025 results call to outline preparations for a pivotal Phase 3 program for pemvidutide in metabolic dysfunction-associated steatohepatit
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
02:15pm, Thursday, 05'th Mar 2026
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
07:00am, Thursday, 05'th Mar 2026
Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD)
Altimmune to Participate in Upcoming Investor Conferences
07:30am, Monday, 02'nd Mar 2026
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
04:40pm, Thursday, 26'th Feb 2026
Altimmune and Novo Nordisk have encountered some headwinds in recent years. Both could rebound, but one of them looks far more likely to do so.
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
07:30am, Thursday, 26'th Feb 2026
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today anno
ALT5 Sigma Corporation Issues Stockholder Letter and Provides Corporate Update
08:00am, Monday, 23'rd Feb 2026
Acting CEO Tony Isaac Outlines Compliance Restoration, Governance Strengthening, and Strategy to Drive Long-Term Stockholder Value LAS VEGAS, NEVADA / ACCESS Newswire / February 23, 2026 / ALT5 Sigma
ALT5 Sigma Corporation Appoints Dr. Adel Elmessiry to Board of Directors
08:00am, Thursday, 12'th Feb 2026
Appointment strengthens ALT5's Board with expertise across AI infrastructure, decentralized systems, and global technology governance LAS VEGAS, NEVADA / ACCESS Newswire / February 12, 2026 / ALT 5 Si
Altimmune (NASDAQ:ALT) Shares Up 7.2% – Time to Buy?
04:41am, Sunday, 01'st Feb 2026
Altimmune, Inc. (NASDAQ: ALT - Get Free Report)'s stock price was up 7.2% during mid-day trading on Friday. The company traded as high as $5.48 and last traded at $5.4650. Approximately 2,268,356 shar
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
05:54pm, Thursday, 29'th Jan 2026
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
01:31pm, Thursday, 29'th Jan 2026
/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27
Altimmune (ALT) Shares Slide On $75 Million Stock Offering
04:13pm, Wednesday, 28'th Jan 2026
Altimmune Inc (NASDAQ: ALT) shares are tumbling on Wednesday following the company's announcement of a $75 million registered direct offering of common stock.
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
09:25pm, Tuesday, 27'th Jan 2026
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced
ALT5 Sigma Corporation to Join Global Leaders at Inaugural World Liberty Forum at Mar-a-Lago
08:00am, Tuesday, 27'th Jan 2026
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (NASDAQ: ALTS) (FRA:5AR1) (“ALT5” or the “Company”), a fintech company that maintains a strategic $WLFI digital asset treasury and provides b
